Evidence map›Paper›PMID 42159835›Full record

ArticleJournal of assisted reproduction and genetics2026

PGT-A reveals triploid embryos among normally fertilized oocytes: frequency and blastocyst features.

Mar Nohales, María José Escribá, Ángel Martín, Aila Coello, Fernanda Insua, María José Santos

Abstract read
In one paragraph

Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mar NohalesIVI-RMA Global, Valencia, Spain. Mar.Nohales@ivirma.com.
María José EscribáIVI-RMA Global, Valencia, Spain.
Ángel MartínIVI-RMA Global Research Alliance, Health Research Institute La Fe, IVI Foundation, Valencia, Spain.
Aila CoelloIVI-RMA Global, Valencia, Spain.
Fernanda InsuaIVI-RMA Global, Valencia, Spain.
María José SantosIVI-RMA Global, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWith the widespread adoption of blastocyst culture and advances in genetic testing technologies enabling reliable determination of ploidy status, the traditional concept of normal fertilization is being re-evaluated. Although the presence of two pronuclei (2PN) is conventionally considered indicative of normal fertilization, not all 2PN-derived embryos are euploid. A proportion of trophectoderm (TE) biopsies analyzed by next-generation sequencing (NGS) for preimplantation genetic testing for aneuploidy (PGT-A) are identified as triploid.

objectivesTo determine whether specific morphological and morphokinetic features can differentiate 2PN-derived triploid blastocysts from 2PN-derived euploid blastocysts.

methodsRetrospective study including 3369 cycles from 2666 patients aged 18-45 years who underwent PGT-A with NGS and single-nucleotide polymorphism (SNP) genotyping of TE biopsies at our IVF center from 2019 to 2023. Among 12,395 analyzed blastocysts, 59 were classified as triploid, originated from 57 PGT-A cycles and belonged to 54 patients. Fertilization assessment was reevaluated. Triploid embryos were analyzed according to second polar body extrusion, day of biopsy (day 5 vs. day 6), the quality of the TE and the inner cell mass (ICM), and morphokinetic parameters (cleavage times from 2- to 5-cell stage). Categorical variables were expressed as proportions. Student's t-test was performed for continuous variables, with a P-value < 0.05 considered statistically significant.

resultsGenetic analysis identified 50 triploid blastocysts derived from 2PN zygotes. Two subpopulation of triploid blastocysts were distinguished: 2 PN 2 polar bodies (PB)-derived and 2PN/1 PB-derived blastocysts. Compared to their euploid sibling embryos, triploid embryos demonstrated (a) significant pronuclear dimorphism, characterized by one PN being significantly larger than the other; (b) delayed morphokinetic parameters, exhibiting slower cell division rates starting from the first cleavage division (t2: 28.59 ± 3.74 h vs. 25.70 ± 2.90 h; t3: 39.76 ± 3.48 vs. 36.75 ± 3.03 h; t4: 40.75 ± 4.07 vs. 37.25 ± 3.66 h; t5: 54.85 ± 8.07 vs. 46.34 ± 5.54 h, respectively; P < 0.05); and (c) reduced embryo quality, with a lower proportion of blastocysts exhibiting high quality TE.

conclusionsThe findings primarily support increased awareness of triploidy risk among embryos derived from apparently normal (2PN) fertilization. Morphological and morphokinetic parameters, although associated with triploidy, do not provide sufficient discriminatory accuracy to replace direct genetic assessment of ploidy, which remains the only reliable method to exclude triploidy. Most 2PN-derived triploid embryos appear to result from retention of the second polar body, highlighting the importance of accurate fertilization checks with special consideration given to the extrusion of the second PB. This consideration is especially relevant in non-PGT-A cycles or when the testing platform does not permit ploidy determination, as triploidy is the most common form of aneuploidy observed in first-trimester miscarriages. The incidence of triploidy in 2PN zygotes may vary across IVF laboratory settings. Given the limited number of triploid embryos identified, these findings should be interpreted with caution.

Indexed as

BlastocystOocytesPreimplantation DiagnosisTriploidyAdolescentAdultAneuploidyEmbryo TransferFemaleFertilization in VitroGenetic TestingHigh-Throughput Nucleotide SequencingHumansMiddle AgedPolymorphism, Single NucleotidePregnancyFertilization checkMolar pregnancyPolar bodiesPreimplantation genetic testing for aneuploidyPronucleiTriploid blastocyst

Identifiers

PMID42159835
PMCPMC13518750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.